Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm that arises from glial cells in the spinal cord. Representative examples include astrocytoma, oligodendroglioma, and ependymoma.
Biomarker and diagnostic research for spinal cord glioma has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and procedural interventions. Pipeline includes 2 PHASE1. Research is primarily sponsored by academic and government institutions.
172 publications have been identified in PubMed for spinal cord glioma. Research spans Review / Meta-Analysis (32%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 55 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:06 PM UTC
Laboratory research | 45 | 26% |
Disease patterns and progression | 19 | 11% |
Testing and diagnosis research | 17 | 10% |
Patient case studies | 16 | 9% |
Clinical study results | 11 | 6% |
New treatment approaches | 7 | 4% |
Other research | 2 | 1% |
Ghasemi DR (2026). [PMID: 41619789](https://pubmed.ncbi.nlm.nih.gov/41619789/). *Neuro Oncol*. [Review / Meta-Analysis]
Huang H (2026). [PMID: 41217375](https://pubmed.ncbi.nlm.nih.gov/41217375/). *International journal of surgery (London, England)*. [Basic Science / Preclinical]
Hack K (2026). [PMID: 41273179](https://pubmed.ncbi.nlm.nih.gov/41273179/). *Neuro Oncol*. [Clinical Trial Publication]
Min HK (2026). [PMID: 40897897](https://pubmed.ncbi.nlm.nih.gov/40897897/). *Nat Biomed Eng*. [Basic Science / Preclinical]
Peng B (2026). [PMID: 41866450](https://pubmed.ncbi.nlm.nih.gov/41866450/). *Neurosci Bull*. [Basic Science / Preclinical]
Farrell CL (2026). [PMID: 28723060](https://pubmed.ncbi.nlm.nih.gov/28723060/). *Unknown Journal*. [Case Report / Case Series]
Wang Y (2026). [PMID: 41796847](https://pubmed.ncbi.nlm.nih.gov/41796847/). *Cancer letters*. [Review / Meta-Analysis]
Mousa AH (2026). [PMID: 41974064](https://pubmed.ncbi.nlm.nih.gov/41974064/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
Lubelski D (2026). [PMID: 42264667](https://pubmed.ncbi.nlm.nih.gov/42264667/). *Neurosurg Clin N Am*. [Review / Meta-Analysis]
Sha Z (2026). [PMID: 41698431](https://pubmed.ncbi.nlm.nih.gov/41698431/). *Neuroscience*. [Basic Science / Preclinical]
AI-curated news mentioning spinal cord glioma
Updated Mar 6, 2026
New CGCG response assessment criteria for spinal cord gliomas have been proposed, aiming to standardize evaluation methods in clinical settings. This development could enhance treatment strategies and patient outcomes in this rare disease.